✦ LIBER ✦

Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: The role of weight-based ribavirin exposure

✍ Scribed by Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Wan-Long Chuang

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 64 KB
Volume: 48
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.22434

No coin nor oath required. For personal study only.

✦ Synopsis

contraindicate the use of drugs such as hydroxymethyl-glutaryl-coenzyme A inhibitors (statins). Statins, as the most popular cholesterollowering agents, are widely used in the MS and display in vitro anti-HCV properties. 6 However, results from an in vivo pilot study with atorvastatin have been disappointing. 7 Moreover, statins are familiar to the diabetologist but perhaps may still raise concern among those caring for (HCV) liver patients. 8 In conclusion, we feel the combined efforts of the basic scientist together with clinical judgement will result in the generation of new ideas eventually conducive to the altered natural course of HCV infection, not only from a virological, but also from a metabolic point of view.

📜 SIMILAR VOLUMES

Rapid virological response in hepatitis

Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure

✍ Chia-Yen Dai; Wan-Long Chuang; Jee-Fu Huang; Ming-Yen Hsieh; Ming-Lung Yu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 1 views

We thank Iorio et al. for their interest in our work and for making us aware of their study, 1 which included some information on liver biopsies in 64 children. Their findings support those of our and other series, namely that chronic hepatitis C in children is generally histologically mild but may

Virologic response rates of weight-based

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

✍ Fred Poordad; Eric Lawitz; Mitchell L. Shiffman; Tarek Hassanein; Andrew J. Muir 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB 👁 1 views

Muir is a consultant for, is on the speakers' bureau of, and received grants from Merck. He received grants from Valeant. He is also a consultant for and received grants from Zynogenetics. Dr. Poordad is a consultant for and received grants from Valeant. Dr. Shiffman advises and received grants from

Impact of weight-based ribavirin with pe

Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1

✍ Ira M. Jacobson; Robert S. Brown Jr; Jonathan McCone; Martin Black; Clive Albert 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB 👁 1 views

Brass, 14 for the WIN-R Study Group WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response

✍ Brian L. Pearlman; Carole Ehleben 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm